Understanding Engagement Trends in Chondrosarcoma Clinical Trials

Key facts

Sponsor

Power Life Sciences Inc.

Principal Investigator

Michael B Gill

Power Life Sciences Inc.

Enrollment

500 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• Power Life Sciences, San Francisco, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Chondrosarcoma

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNANCT07360964
  Clear Cell Chondrosarcoma in Italy
  Istituto Ortopedico Rizzoli
• RECRUITINGNCT07315542
  Diagnostic and Therapeutic Targets in Cartilaginous Tumours
  St. Anne's University Hospital Brno, Czech Republic
• RECRUITINGEARLY PHASE1NCT06645808
  PET-imaging of Two Vartumabs in Patients With Solid Tumors
  Var2 Pharmaceuticals
• RECRUITINGPHASE3NCT06127407
  Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
  Servier Bio-Innovation LLC
• RECRUITINGNCT06486506
  Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic Results
  Costantino Errani
• RECRUITINGPHASE2NCT06176989
  Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
  National Cancer Institute (NCI)
• RECRUITINGNANCT06387485
  A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
  Ricoh USA, Inc.
• ACTIVE NOT RECRUITINGPHASE2NCT05836571
  Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
  National Cancer Institute LAO

See all trials for Chondrosarcoma →